A rapid and scalable framework for evaluating novel precision medicine strategies using biologically-relevant patient-derived 3D cell models

Overview

Traditional approaches to personalized therapy screening are often slow, variable, and difficult to scale. In this application note, we demonstrate how the RASTRUM™ Allegro platform, combined with OncoPro™ Tumoroid Cell Lines and Culture Media from Thermo Fisher Scientific, enables a rapid and reproducible framework for evaluating novel precision medicine strategies.

Using patient-derived colorectal cancer tumoroids, we establish a workflow that maintains subtype-specific molecular features, supports multiplexed drug testing, and generates actionable therapeutic insights—all in just 8 weeks. With seamless integration of RASTRUM Cloud and matrix optimization tools, this approach offers a scalable and translationally relevant alternative to traditional preclinical models.

Highlights

• Rapid evaluation of therapy response using patient-derived 3D tumoroid models
• 8-week end-to-end workflow—from model creation to drug screening
• Preservation of molecular subtype features and biomarker fidelity
• Reproducible tumoroid morphology and growth in synthetic hydrogels
• Discovery of biomarker–therapy relationships, including LCN2–itraconazole sensitivity
• Ideal for precision oncology workflows requiring throughput, speed, and biological relevance